145 related articles for article (PubMed ID: 37424799)
1. Visualized machine learning models combined with propensity score matching analysis in single PR-positive breast cancer prognosis: a multicenter population-based study.
Li C; Hui Y; Wei X; Yao P; Jia Y; Liu M; Wang Y; Li J; Cai Y; Zhang Y; Feng Z; Zhang Y; Zhang S; Du C
Am J Cancer Res; 2023; 13(6):2234-2253. PubMed ID: 37424799
[TBL] [Abstract][Full Text] [Related]
2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
3. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract][Full Text] [Related]
4. Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.
Zhang S; Liu Y; Liu X; Liu Y; Zhang J
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831499
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
6. The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status.
Zhao H; Gong Y
Front Oncol; 2021; 11():643956. PubMed ID: 34079755
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.
Zheng H; Ge C; Lin H; Wu L; Wang Q; Zhou S; Tang W; Zhang X; Jin X; Xu X; Hong Z; Fu J; Du J
Int J Clin Oncol; 2022 Jul; 27(7):1145-1153. PubMed ID: 35397755
[TBL] [Abstract][Full Text] [Related]
8. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score.
Yang ZJ; Liu YX; Huang Y; Chen ZJ; Zhang HZ; Yu Y; Wang X; Cao XC
Cancer Med; 2023 Feb; 12(3):2493-2504. PubMed ID: 35909232
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Models Using Machine Learning Algorithms and Treatment Outcomes of Occult Breast Cancer Patients.
Qu J; Li C; Liu M; Wang Y; Feng Z; Li J; Wang W; Wu F; Zhang S; Zhao X
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176539
[TBL] [Abstract][Full Text] [Related]
10. Machine learning predicts the prognosis of breast cancer patients with initial bone metastases.
Li C; Liu M; Li J; Wang W; Feng C; Cai Y; Wu F; Zhao X; Du C; Zhang Y; Wang Y; Zhang S; Qu J
Front Public Health; 2022; 10():1003976. PubMed ID: 36225783
[TBL] [Abstract][Full Text] [Related]
11. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
12. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
13. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study.
Schiza A; Mauri D; Fredriksson I; Anna-Karin Wennstig ; Valachis A
Breast Cancer Res Treat; 2021 Apr; 186(3):779-789. PubMed ID: 33258078
[TBL] [Abstract][Full Text] [Related]
14. Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC.
Zheng S; Li L; Chen M; Yang B; Chen J; Liu G; Shao Z; Wu J
Breast; 2022 Jun; 63():177-186. PubMed ID: 35429731
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
16. 21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy.
Chevli N; Haque W; Tran KT; Farach AM; Schwartz MR; Hatch SS; Butler EB; Teh BS
Radiother Oncol; 2022 Sep; 174():37-43. PubMed ID: 35772577
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
[TBL] [Abstract][Full Text] [Related]
19. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
20. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
